Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).
The 21-valent product – formerly known as V116 – covers a wider range of Streptococcus pneumoniae serotypes than any of MSD’s earlier vaccines and eight that are not covered by any other ...
One of these – dubbed V116 – is a cocktail of 21 Streptococcus pneumoniae serotypes designed to have the most benefit in adult populations, and it has just cleared a phase 1/2 trial as it ...
MyChesCo on MSN7mon
FDA Approves New Pneumococcal Vaccine for AdultsCapvaxive, manufactured by Merck Sharp & Dohme LLC, is designed to prevent diseases caused by 22 different serotypes of ...
GlobalData on MSN3mon
MSD’s CAPVAXIVE vaccine shows promise in pneumococcal disease trialCAPVAXIVE was found to be immunogenic for all 21 serotypes included in ... to prevent invasive disease and pneumonia caused ...
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...
Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback